OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
OSR Holdings (NASDAQ: OSRH) has signed a term sheet to acquire Woori IO (WORIO), a South Korean company developing noninvasive glucose monitoring technology. The acquisition will be executed through OSR's Korean affiliate, OSRK, with WORIO becoming its wholly-owned subsidiary.
The deal structure allows WORIO shareholders to receive OSRK shares, potentially convertible to OSRH shares at a 1:12.96 ratio if OSRH's stock reaches $10.00 within three years. WORIO's technology uses near-infrared spectroscopy for needle-free glucose monitoring, targeting the $40 billion blood glucose monitoring market expected by 2030.
WORIO has completed a proof-of-concept study with Korea University Hospital and was selected for Samsung Electronics' C-Lab Outside program in Q1 2025. The agreement includes a 6-month exclusivity period for due diligence completion.
OSR Holdings (NASDAQ: OSRH) ha firmato un term sheet per acquisire Woori IO (WORIO), un'azienda sudcoreana che sviluppa tecnologia per il monitoraggio non invasivo della glicemia. L'acquisizione sarà realizzata tramite la filiale coreana di OSR, OSRK, con WORIO che diventerà una sua controllata al 100%.
La struttura dell'accordo permette agli azionisti di WORIO di ricevere azioni di OSRK, potenzialmente convertibili in azioni OSRH con un rapporto di 1:12,96 se il prezzo del titolo OSRH raggiungerà 10,00 $ entro tre anni. La tecnologia di WORIO utilizza la spettroscopia nel vicino infrarosso per un monitoraggio della glicemia senza aghi, puntando al mercato del monitoraggio del glucosio nel sangue da 40 miliardi di dollari previsto entro il 2030.
WORIO ha completato uno studio di fattibilità con il Korea University Hospital ed è stata selezionata per il programma C-Lab Outside di Samsung Electronics nel primo trimestre del 2025. L'accordo prevede un periodo di esclusiva di 6 mesi per il completamento della due diligence.
OSR Holdings (NASDAQ: OSRH) ha firmado un term sheet para adquirir Woori IO (WORIO), una empresa surcoreana que desarrolla tecnología para la monitorización no invasiva de glucosa. La adquisición se llevará a cabo a través de la filial coreana de OSR, OSRK, y WORIO se convertirá en una subsidiaria totalmente propiedad de OSRK.
La estructura del acuerdo permite que los accionistas de WORIO reciban acciones de OSRK, que podrían convertirse en acciones de OSRH en una proporción de 1:12,96 si el precio de la acción de OSRH alcanza los 10,00 $ en un plazo de tres años. La tecnología de WORIO utiliza espectroscopía en el infrarrojo cercano para el monitoreo de glucosa sin agujas, apuntando al mercado de monitoreo de glucosa en sangre de 40 mil millones de dólares esperado para 2030.
WORIO ha completado un estudio de prueba de concepto con el Korea University Hospital y fue seleccionada para el programa C-Lab Outside de Samsung Electronics en el primer trimestre de 2025. El acuerdo incluye un período de exclusividad de 6 meses para la finalización de la due diligence.
OSR Holdings (NASDAQ: OSRH)가 비침습 혈당 모니터링 기술을 개발하는 한국 기업 Woori IO (WORIO)를 인수하기 위한 조건서를 체결했습니다. 이번 인수는 OSR의 한국 자회사인 OSRK를 통해 진행되며, WORIO는 OSRK의 100% 자회사가 됩니다.
거래 구조는 WORIO 주주들이 OSRK 주식을 받을 수 있도록 하며, OSRH 주가가 3년 내에 10.00달러에 도달하면 1:12.96 비율로 OSRH 주식으로 전환될 수 있습니다. WORIO의 기술은 바늘 없는 혈당 모니터링을 위해 근적외선 분광법을 사용하며, 2030년까지 400억 달러 규모의 혈당 모니터링 시장을 목표로 하고 있습니다.
WORIO는 고려대학교 병원과 개념 증명 연구를 완료했으며, 2025년 1분기에 삼성전자 C-Lab Outside 프로그램에 선정되었습니다. 이번 계약에는 실사 완료를 위한 6개월 독점 기간이 포함되어 있습니다.
OSR Holdings (NASDAQ : OSRH) a signé une lettre d'intention pour acquérir Woori IO (WORIO), une entreprise sud-coréenne développant une technologie de surveillance non invasive de la glycémie. L'acquisition sera réalisée via la filiale coréenne d'OSR, OSRK, WORIO devenant une filiale en propriété exclusive.
La structure de l'accord permet aux actionnaires de WORIO de recevoir des actions OSRK, potentiellement convertibles en actions OSRH selon un ratio de 1:12,96 si le cours de l'action OSRH atteint 10,00 $ dans les trois ans. La technologie de WORIO utilise la spectroscopie proche infrarouge pour une surveillance du glucose sans aiguille, visant le marché du contrôle du glucose sanguin estimé à 40 milliards de dollars d'ici 2030.
WORIO a achevé une étude de preuve de concept avec l'hôpital de l'Université de Corée et a été sélectionnée pour le programme C-Lab Outside de Samsung Electronics au premier trimestre 2025. L'accord inclut une période d'exclusivité de 6 mois pour finaliser la due diligence.
OSR Holdings (NASDAQ: OSRH) hat ein Term Sheet zur Übernahme von Woori IO (WORIO), einem südkoreanischen Unternehmen, das nicht-invasive Glukoseüberwachungstechnologie entwickelt, unterzeichnet. Die Übernahme wird über OSRs koreanische Tochtergesellschaft OSRK abgewickelt, wobei WORIO eine hundertprozentige Tochtergesellschaft von OSRK wird.
Die Struktur des Deals ermöglicht es den WORIO-Aktionären, OSRK-Aktien zu erhalten, die bei Erreichen eines OSRH-Aktienkurses von 10,00 $ innerhalb von drei Jahren möglicherweise im Verhältnis 1:12,96 in OSRH-Aktien umgewandelt werden können. Die Technologie von WORIO nutzt Nahinfrarotspektroskopie für eine nadelfreie Glukosemessung und zielt auf den bis 2030 erwarteten 40-Milliarden-Dollar-Blutzuckermarkt ab.
WORIO hat eine Machbarkeitsstudie mit dem Korea University Hospital abgeschlossen und wurde im ersten Quartal 2025 für das C-Lab Outside Programm von Samsung Electronics ausgewählt. Die Vereinbarung beinhaltet eine 6-monatige Exklusivitätsphase zur Durchführung der Due Diligence.
- Strategic entry into the rapidly growing glucose monitoring market projected to reach $40B by 2030
- WORIO's noninvasive technology eliminates need for needles or sensors, offering competitive advantage
- Successful proof-of-concept study completed with Korea University Hospital
- Strategic partnership with Samsung Electronics through C-Lab Outside program
- Potential integration with wearable devices like smart watches expands market opportunities
- Deal completion contingent on OSRH stock reaching $10.00 within 3 years
- Larger confirmatory trial still needed for MFDS medical device approval
- Technology still in development phase with no regulatory approvals yet
- Complex share exchange structure with potential renegotiation if stock price condition not met
Insights
OSR Holdings' potential acquisition of Woori IO could position it in the rapidly growing noninvasive glucose monitoring market worth $40B+ by 2030.
OSR Holdings has signed a term sheet to acquire Woori IO, positioning itself to enter the lucrative noninvasive glucose monitoring market. The proposed structure would make Woori IO a wholly-owned subsidiary of OSR's Korean affiliate (OSRK), with Woori IO shareholders receiving OSRK shares potentially convertible to OSRH NASDAQ-traded stock at a 1:12.96 ratio if OSRH reaches
What makes this acquisition strategically significant is Woori IO's proprietary near-infrared spectroscopy technology that measures glucose without needles or skin penetration—a truly noninvasive approach unlike current continuous glucose monitors (CGMs). Woori IO has completed a proof-of-concept study with Korea University Hospital and plans to enter larger confirmatory trials for regulatory approval in Korea.
The glucose monitoring market context is compelling: projected to exceed
Notably, Woori IO's technology is being developed for integration into consumer wearables like smartwatches, evidenced by their selection for Samsung Electronics' startup program in Q1 2025. This positions OSR to potentially capture value across both medical and consumer technology segments.
The 6-month exclusivity period for due diligence indicates a relatively advanced stage in negotiations, though several contingencies remain before definitive agreements can be finalized. The transaction structure, particularly the stock price-dependent conversion terms, suggests confidence in potential value creation but also introduces execution risk.
Under the proposed structure, WORIO will become a wholly owned subsidiary of OSRK. Shareholders of WORIO will receive newly issued shares of OSRK through the share exchange and may be eligible to convert them into OSRH common stock traded on NASDAQ, subject to certain conditions including "
Specifically, WORIO shareholders may convert their OSRK shares into OSRH shares at a fixed exchange ratio of 1 OSRK share = 12.96 OSRH shares, provided that OSRH's stock price reaches
WORIO's proprietary platform uses near-infrared spectroscopy (NIRS) to measure glucose without needles, sensors, or skin penetration — representing a truly noninvasive alternative to today's continuous glucose monitors (CGMs). Its solution aims to eliminate the burden of pain and daily finger pricks for millions of people with diabetes. According to recent global market research, the blood glucose monitoring devices market is expected to exceed
WORIO has completed a proof-of-concept study with the Korea University Hospital (Guro) to validate the accuracy and effectiveness of its prototype devices and the data measured by them, based on which the company plans to enter a larger confirmatory trial to be registered with the Ministry of Food and Drug Safety (MFDS) of
"We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact," said Peter Hwang, CEO of OSRH. "Woori IO's breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market."
Following the signing of this Term Sheet, both parties will proceed with due diligence and aim to execute definitive agreements within the 6 months exclusivity period.
About OSR Holdings, Inc.
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development. For more information, visit www.OSR-Holdings.com.
About Woori IO Co., Ltd.
Woori IO is a medical device company based in Jeonju,
Contact:
Investor Relations
OSR Holdings, Inc.
Email: IR@osr-holdings.com
Website: www.OSR-Holdings.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-enters-into-term-sheet-to-acquire-woori-io-a-pioneer-in-noninvasive-glucose-monitoring-technology-302512926.html
SOURCE OSR Holdings Inc.
FAQ
What are the terms of OSR Holdings' acquisition of Woori IO?
What is Woori IO's glucose monitoring technology?
How big is the glucose monitoring market that OSRH is entering?
What clinical validation has Woori IO completed?
What is the timeline for the OSRH-Woori IO acquisition?
How does WORIO's technology compare to current glucose monitoring solutions?
